[{"id":"19be524b-4248-4054-97ea-82c45566fa0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02540876","created_at":"2021-01-18T12:17:34.359Z","updated_at":"2024-07-02T16:37:00.329Z","phase":"Phase 1","brief_title":"Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02540876","lead_sponsor":"University of Chicago","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A deletion • CDKN2A mutation","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDKN2A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ilorasertib (ABT348)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/08/2015","start_date":" 09/08/2015","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 02/08/2019","study_completion_date":" 02/08/2019","last_update_posted":"2019-04-22"},{"id":"293aa130-f843-4e6e-b244-1c52e1d1dad3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01324830","created_at":"2021-01-18T05:23:43.525Z","updated_at":"2024-07-02T16:37:04.485Z","phase":"Phase 1a/1b","brief_title":"Monotherapy Dose Finding With BI 847325 in Solid Tumours","source_id_and_acronym":"NCT01324830","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • RAS mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI 847325"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 04/15/2011","start_date":" 04/15/2011","primary_txt":" Primary completion: 06/06/2013","primary_completion_date":" 06/06/2013","study_txt":" Completion: 10/10/2013","study_completion_date":" 10/10/2013","last_update_posted":"2018-12-21"},{"id":"a40d2096-ed24-41fd-89c0-83c2668d15ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639248","created_at":"2021-01-18T07:02:56.960Z","updated_at":"2024-07-02T16:37:20.654Z","phase":"Phase 2","brief_title":"Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC","source_id_and_acronym":"NCT01639248","lead_sponsor":"CASI Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENMD-2076"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2017-06-26"}]